Dianthus Therapeutics, Inc. /DE/ (DNTH) Current Ratio
- Current ratio · latest quarter: Value 26.10×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 26.10× | Current assets / current liabilities. $897.54M ÷ $34.39M ≈ 26.10× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 897.54M USD | Assets, Current |
| Current obligations | 34.39M USD | Liabilities, Current |
| Cash and equivalents | 110.55M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 106.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 6.39M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $897.54M | $34.39M | $110.55M | (m) | $106.00K | (m) | $6.39M | (m) | 26.10× |
| 2026-03-31 | $1.12B | $38.28M | $627.67M | $287.03M | $1.23M | (m) | $5.27M | (m) | 29.25× |
| 2025-12-31 | $409.44M | $30.73M | $51.09M | (m) | $52.00K | (m) | $9.72M | (m) | 13.32× |
| 2025-09-30 | $413.82M | $23.86M | $55.98M | (m) | $5.00M | (m) | $6.71M | (m) | 17.35× |
| 2025-06-30 | $263.61M | $20.09M | $13.24M | (m) | $39.00K | (m) | $5.40M | (m) | 13.12× |
| 2025-03-31 | $271.00M | $16.95M | $10.12M | (m) | $1.00M | (m) | $8.27M | (m) | 15.99× |
| 2024-12-31 | $280.90M | $18.45M | $22.79M | (m) | $0.00 | (m) | $4.58M | (m) | 15.22× |
| 2024-09-30 | $287.49M | $15.71M | $33.67M | (m) | $1.39M | (m) | $7.57M | (m) | 18.30× |
| 2024-06-30 | $365.69M | $10.03M | $314.17M | (m) | $840.00K | (m) | $3.69M | (m) | 36.46× |
| 2024-03-31 | $380.93M | $8.96M | $329.72M | (m) | $435.00K | (m) | $2.61M | (m) | 42.52× |
| 2023-12-31 | $177.45M | $9.63M | $132.32M | (m) | $294.00K | (m) | $2.61M | (m) | 18.42× |
| 2023-09-30 | $191.45M | $13.08M | $157.28M | (m) | $232.00K | (m) | $1.37M | (m) | 14.64× |
| 2023-06-30 | $78.64M | $4.03M | $62.63M | $14.96M | (m) | (m) | $813.00K | (m) | 19.49× |
| 2023-03-31 | $83.44M | $5.98M | $48.52M | $29.68M | (m) | (m) | $1.08M | (m) | 13.95× |
| 2022-12-31 | $82.03M | $8.22M | $15.37M | (m) | $4.70M | (m) | $1.17M | (m) | 9.97× |
| 2022-09-30 | $132.10M | $12.92M | $59.03M | $69.26M | (m) | (m) | $2.58M | (m) | 10.22× |
| 2022-06-30 | $142.04M | $11.26M | $54.83M | $84.59M | (m) | (m) | $2.05M | (m) | 12.62× |
| 2022-03-31 | $160.24M | $14.09M | $71.77M | $84.84M | (m) | (m) | $4.44M | (m) | 11.37× |
| 2021-12-31 | $9.39M | $5.35M | $7.64M | (m) | $469.00K | (m) | $1.36M | (m) | 1.75× |
| 2021-09-30 | $196.47M | $10.15M | $157.54M | $35.08M | (m) | (m) | $1.89M | (m) | 19.36× |
| 2021-06-30 | $210.19M | $11.08M | $155.03M | $52.77M | (m) | (m) | $2.93M | (m) | 18.96× |
| 2021-03-31 | $135.10M | $9.21M | $49.29M | $83.00M | (m) | (m) | $2.11M | (m) | 14.67× |
| 2020-12-31 | $151.53M | $11.43M | $58.15M | $90.68M | (m) | (m) | $3.76M | (m) | 13.26× |
| 2020-09-30 | $164.27M | $9.86M | $141.68M | $20.05M | (m) | (m) | $2.39M | (m) | 16.65× |
| 2020-06-30 | $179.88M | $10.37M | $136.29M | $40.21M | (m) | (m) | $2.65M | (m) | 17.35× |
| 2020-03-31 | $133.13M | $12.70M | $74.93M | $55.47M | (m) | (m) | $3.95M | (m) | 10.48× |
| 2019-12-31 | $149.84M | $14.12M | $65.07M | $80.66M | (m) | (m) | $2.81M | (m) | 10.62× |
| 2019-09-30 | $165.23M | $9.63M | $85.51M | $75.06M | (m) | (m) | $2.04M | (m) | 17.16× |
| 2019-06-30 | $183.01M | $9.94M | $33.11M | $139.16M | (m) | (m) | $2.35M | (m) | 18.41× |
| 2019-03-31 | $135.08M | $7.92M | $31.24M | $96.07M | (m) | (m) | $3.01M | (m) | 17.06× |
| 2018-12-31 | $145.32M | $10.42M | $58.34M | $84.22M | (m) | (m) | $3.49M | (m) | 13.95× |
| 2018-09-30 | $162.86M | $11.93M | $159.67M | (m) | (m) | (m) | $4.90M | (m) | 13.65× |
| 2018-06-30 | $175.93M | $7.61M | $173.43M | (m) | (m) | (m) | $1.50M | (m) | 23.13× |
| 2017-12-31 | $52.50M | $4.14M | $51.40M | (m) | (m) | (m) | $167.00K | (m) | 12.68× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |